# Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

> **NCT01301599** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 308 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** combination therapy
- **DRUG:** alpha blocker monotherapy
- **DRUG:** 5 alpha reductase inhibitor monotherapy

## Key facts

- **NCT ID:** NCT01301599
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-07
- **Final completion:** 2013-12
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301599, "Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01301599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*